{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["5(9)"],"submitter":["Hellmann-Regen J"],"pubmed_abstract":["<h4>Importance</h4>Insufficient treatment response and resulting chronicity constitute a major problem in depressive disorders. Remission rates range as low as 15% to 40% and treatment-resistant depression (TRD) is associated with low-grade inflammation, suggesting anti-inflammatory interventions as a rational treatment strategy. Minocycline, which inhibits microglial activation, represents a promising repurposing candidate in the treatment of TRD.<h4>Objective</h4>To determine whether 6 weeks of minocycline as add-on to antidepressant treatment as usual can significantly reduce depressive symptoms in patients with TRD.<h4>Design, setting, and participants</h4>The study was conducted in Germany and designed as a multicenter double-blind randomized clinical trial (RCT) of 200 mg/d minocycli"],"journal":["JAMA network open"],"pagination":["e2230367"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9475381"],"repository":["biostudies-literature"],"pubmed_title":["Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial."],"pmcid":["PMC9475381"],"pubmed_authors":["Gruber O","Rupprecht R","Heuser I","Wiltfang J","Prvulovic D","Manook A","Clemens V","Baghai TC","Padberg F","Uhr M","Hellmann-Regen J","Huber C","Kornhuber J","Goya-Maldonado R","Ising M","Reif A","Schule C","Grozinger M","Friede T"],"additional_accession":[]},"is_claimable":false,"name":"Effect of Minocycline on Depressive Symptoms in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.","description":"<h4>Importance</h4>Insufficient treatment response and resulting chronicity constitute a major problem in depressive disorders. Remission rates range as low as 15% to 40% and treatment-resistant depression (TRD) is associated with low-grade inflammation, suggesting anti-inflammatory interventions as a rational treatment strategy. Minocycline, which inhibits microglial activation, represents a promising repurposing candidate in the treatment of TRD.<h4>Objective</h4>To determine whether 6 weeks of minocycline as add-on to antidepressant treatment as usual can significantly reduce depressive symptoms in patients with TRD.<h4>Design, setting, and participants</h4>The study was conducted in Germany and designed as a multicenter double-blind randomized clinical trial (RCT) of 200 mg/d minocycli","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Sep","modification":"2026-06-01T02:24:17.498Z","creation":"2025-04-04T12:05:15.371Z"},"accession":"S-EPMC9475381","cross_references":{"pubmed":["36103181"],"doi":["10.1001/jamanetworkopen.2022.30367"]}}